Kelly Louise Morrison
Trade Performance Intelligence
Score: 4/10Performance calculated from trade date to most recent market close. Real-time stock data from Financial Modeling Prep. This is not financial advice.
Stock Price at Trade vs. Today
Real market data showing how each stock moved since the congress member traded it.
Suspicious Timing Detected
3 flagsRep. Morrison sold $15,001-$50,000 in $TMO on 2025-08-19 — 22 days before the RESULTS Act (HR5269) was introduced, which aims to stabilize Medicare reimbursement rates for clinical diagnostic laboratory tests.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $15K-$50K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $15K-$50K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $15K-$50K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $15K-$50K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $ACN | Accenture plc Class A Ordinary Shares | $1K-$15K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $1K-$15K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $1K-$15K | — | — | — | Aug 19, 2025 |
| PARTIAL SELL | $TMO | Thermo Fisher Scientific Inc Common Stock | $1K-$15K | — | — | — | Aug 19, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
PrEP and PEP are Prevention Act
The PrEP and PEP are Prevention Act mandates no-cost coverage for HIV prevention drugs and related services, directly increasing demand for these medications and associated diagnostic tests. This legislation creates a guaranteed market expansion for pharmaceutical companies producing PrEP/PEP drugs and diagnostic providers, while increasing costs for health insurers.
RESULTS Act
The RESULTS Act (HR5269) aims to stabilize Medicare reimbursement rates for clinical diagnostic laboratory tests, preventing future payment reductions. This bill is in the early stages of the legislative process, having been introduced and referred to two House committees. Its current impact on market prices for diagnostic testing companies is not yet significant due to its early legislative stage.
Biosimilar Red Tape Elimination Act
The Biosimilar Red Tape Elimination Act, HR5526, if enacted, would automatically grant interchangeability to biosimilar products, reducing market exclusivity for innovator biologic manufacturers. This bill is in the early stages, having been referred to the House Committee on Energy and Commerce on September 19, 2025. Innovator biologic manufacturers like Amgen, Johnson & Johnson, and Biogen face potential market share erosion, while biosimilar producers like Viatris and Teva could benefit.
Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act
The Ian Kalvinskas Pediatric Liver Cancer Early Detection and Screening Act mandates HHS to promote newborn liver disease screenings, creating a new market for diagnostic tests and related services. This directly increases demand for early detection tools and follow-up care for pediatric liver conditions. Diagnostic companies stand to gain from increased testing volumes.
ACCENTURE FEDERAL SERVICES LLC: $12.0M Department of Justice Contract
Accenture Federal Services LLC, a subsidiary of Accenture plc ($ACN), secured a $12.0 million BPA Call from the FBI for EPAS Services. This contract represents a negligible portion of Accenture's annual revenue and is a routine award for IT services.
To authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of certain countries.
HR5917 authorizes the President to grant normal trade relations (NTR) status to most countries, excluding Belarus, Cuba, and North Korea, by waiving the Jackson-Vanik amendment. This action reduces tariffs and trade barriers for goods from these countries, directly benefiting U.S. importers and consumers through lower costs. Companies relying on global supply chains will see improved margins and increased access to goods.
Protecting Free Vaccines Act of 2025
The 'Protecting Free Vaccines Act of 2025' (S.2857) is in the early stages, having been referred to committee. This bill aims to codify existing mandates for ACIP-recommended immunization coverage, ensuring stable revenue for vaccine manufacturers and health insurers by preventing future disruptions to current vaccine coverage. It does not introduce new market drivers or significant changes to demand.
Foreign Robocall Elimination Act
The Foreign Robocall Elimination Act establishes an interagency taskforce to combat unlawful robocalls, increasing demand for advanced analytics and fraud prevention solutions. This directly benefits cybersecurity and analytics providers while increasing compliance costs for telecommunication companies. The bill creates a new market for specialized anti-robocall technologies.
Protecting Free Vaccines Act
The 'Protecting Free Vaccines Act' (HR5448) is an early-stage bill that, if enacted, would mandate no-cost coverage for ACIP-recommended vaccines by Medicare, Medicaid, CHIP, and private insurers until January 1, 2030. This would directly increase demand for vaccine manufacturers and shift cost burdens to health insurers and government programs. Vaccine manufacturers are positioned for sustained revenue growth, while health insurers face increased costs.
Ensuring Patient Access to Critical Breakthrough Products Act
The 'Ensuring Patient Access to Critical Breakthrough Products Act' (HR5343) has advanced out of committee, indicating significant legislative momentum for expedited Medicare coverage of FDA-designated breakthrough medical devices. This bill directly benefits manufacturers by removing a key barrier to market adoption and revenue generation. Companies like Medtronic, Intuitive Surgical, Abbott Laboratories, Johnson & Johnson, and Becton, Dickinson and Company are positioned to gain from this accelerated market access.
Live Charts
Other Filings by Kelly Louise Morrison
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.